Anti-Trust Policy

Congress Must Ban Kickbacks, Promote Competition in Drug Markets to End Shortages and High Prices

Investor’s Business Daily, April 2, 2018 –


A new study by the Schaeffer Center for Health Policy at USC highlights the need for decisive action by the President, Congress, and federal anti-trust regulators to curb abuses by medical market middlemen that are driving up prices, causing drug shortages, and harming patients.  The USC study found that 1.6 million consumers overpaid $135 million during 2013 because pharmacy benefit managers (PBMs), which administer prescription claims for insurance companies, charged co-pays higher than drug retail prices.

An even greater problem is an obscure provision of the Medicare law that allows medical market middlemen like PBMs and group purchasing organizations (GPOs), which act as purchasing agents for large healthcare institutions, to demand kickback payments from drug companies in exchange for exclusive sales contracts.  This misguided law and the system of anti-competitive kickbacks it has spawned have caused severe drug shortages exceeding 400 annually for most of the decade and price increases harmful to patients across America.

Drug Shortages TV Graphic.jpeg

This situation is tragic and unnecessary.  The original Medicare law wisely contained an anti-kickback provision that made it illegal to pay or receive kickbacks in exchange for any contract for medical products or services paid for with government funds.  Lobbyists for GPOs convinced Congress in 1987 to grant them an exemption, known as a “safe harbor,” from having to comply with the Medicare anti-kickback provision.   Federal regulators kissed the industry on the other cheek in 2003 by extending the exemption to PBMs.

The kickback scheme created by the “safe harbor” is directly responsible for drug shortages and price hikes because it has destroyed the economic incentive to produce many critical life-saving medicines.  GPO kickbacks have strangled drug makers’ profit margins so severely that they can’t earn a sufficient financial return to justify remaining in production.

Furthermore, with their profits under siege by GPOs, many drug companies have not been able to afford to invest adequately in plant maintenance and quality control.  This has exposed them to warning letters, fines, and plant shutdowns resulting from adverse FDA inspections as well as expensive product recalls and settlements in liability lawsuits stemming from contaminated medicines. This combination of high risk and low profit has driven many manufacturers out of the market leaving the U.S. with only one or two suppliers of critical drugs.

Continue Reading

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s